Prelude Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-186,591	Closed	-$418K	–	1446
2024 Q2	$418K	Buy	186,591 +130,698	+234%	+$293K	0.03%	554
2024 Q1	$160K	Sell	55,893 -133,983	-71%	-$385K	0.01%	1038
2023 Q4	$336K	Sell	189,876 -50,375	-21%	-$89.2K	0.02%	586
2023 Q3	$759K	Buy	+240,251	New	+$759K	0.05%	302